Browsing: biopharmaceuticals

BioVaxys Technology Corp. settles $60,000 debt through issuance of 1,200,000 common shares

BioVaxys Technology Corp. announces the revocation of the management cease trade order and completion of debt settlement

The article discusses the challenges and opportunities in global market access for biopharmaceuticals, particularly cell and gene therapies, and the role of health-technology assessments in determining their reimbursement and accessibility.

A Northeastern University professor is developing an AI-driven methodology to improve the creation of life-saving biopharmaceuticals.

BioVaxys Technology Corp. has received a management cease trade order (MCTO) from the British Columbia Securities Commission due to delays in filing its audited annual financial statements.